Navigation Links
RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences
Date:9/10/2009

The formation of RiversEdge BioVentures LLC is announced today by Principal and Founder, David A. Dodd.

Beaufort, SC (Vocus) - The formation of RiversEdge BioVentures LLC is announced today by Principal and Founder, David A. Dodd.

Prior to forming RiversEdge BioVentures LLC, Mr. Dodd achieved a highly distinguished career, serving in executive positions in several major pharmaceutical and life sciences companies.

Recently, Mr. Dodd served as President, CEO and Chairman of BioReliance Corporation, as an equity partner with Avista Capital Partners in establishing that organization as a stand-alone company following its purchase from Invitrogen Corporation (now, Life Technology, Inc.).

In addition, Mr. Dodd served as the non-executive Chairman of Stem Cell Sciences Plc. (LSE:AIM STEM; ASX: STC), leading a strategic transformation and eventual sale of that company to Stem Cells Inc. in April, 2009. Mr. Dodd also served on the Board of Stheno Corporation, a private life sciences technology company.

From June 2000 to July 2006, Mr. Dodd served as President, CEO and Director of Serologicals Corporation (NASDAQ: SERO), until the sale of Serologicals to Millipore Corporation (NYSE: MIL) in July, 2006.

From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., and as a member of the Management Board for the Pharmaceutical Sector for Solvay S.A. Mr. Dodd also served as Chairman of the Board of Unimed Pharmaceuticals, Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with major life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories.

Mr. Dodd holds a Bachelor of Science and Master of Science from Georgia State University and completed the Harvard Business School Advanced Management
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Newbridge Securities Corporation Forms BioVentures Division
3. Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
4. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
5. CardioDynamics Provides 2007 Shareholder Meeting Update
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
8. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
9. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...EW YORK, Nov. 19 NeoStem... has sent the following letter to its shareholders... 30, 2009, of China Biopharmaceuticals Holdings, I...ny based in the People,s Republic of China. The me...uzhou Eyre Pharmaceutical Co. Ltd., CHBP,s primary...
(Date:11/19/2009)...ONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutic...ient in a randomized Phase 2B study of AEG35156, a...opment for multiple oncology indications. ,, Th...2 Study of the X-Linked Inhibitor of Apoptosis (XI...igh-dose Cytarabine and Idarubicin in AML Followin...
(Date:11/19/2009)..., VIENNA, Austria, November 19 /PRNewswire/ -...ogram on one product candidate at an unexpectedly ...AD02 is planned to enter into,Phase II clinical tr...mediately follows the completion of two Phase I tr...y based its fast decision on the first interim,ana...
(Date:11/18/2009)...N, Ill. Imagine a polka-dotted postage stamp that...mply by changing colors. , As reported in the Se...nneth Suslick and his team at the University of Il...eneral detection of toxic industrial chemicals (TI...s by visualizing odors. This sensor array could b...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
... Sept. 18 Ingenuity Systems, the,leading provider...cientific,literature and data, is pleased to annou... major public-private biomedical research,partners...biological,markers to support new drug development...he founding members of the Consortium include the ...
...er 18 - Clinical Study Demonstrates Breakthrough... Capacities and Expands Potential Production,Capac... Sanofi pasteur, the vaccines division of sanofi-...ts new investigational H5N1 pandemic influenza,vac...high immune response,at the lowest dose of H5N1 an...
...e University of Pennsylvania have developed nanowi...ears and retrieving that data a thousand times fas...Flash memory and micro-drives, all using less powe...tesh Agarwal, an assistant professor in the Depart...leagues developed a self-assembling nanowire of ge...
Other Biology Technology:Ingenuity Systems Joins Biomarkers Consortium 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 3Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 4Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 5Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 2Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 3
(Date:11/20/2009)...h 2009 - Bacteria possess an ingenious mechanism f...cks of the cell. This is the new finding of a team... a life sciences research institute in Flanders, B...l. The scientists made this discovery by modifying...coli . By means of this model organism, they have ...
(Date:11/20/2009)...ulmonary disease (COPD), a respiratory disease com... the fourth leading cause of death worldwide. 600...rs have yet to find any real treatment or cure, Gr...niversity of Western Ontario in London, Canada, is...ght into the disease. , Parraga is a scienti...
(Date:11/19/2009)...rring brain chemical with an unwieldy name: 4-hydr...ed or used as a date-rape drug. , Now, a team o... routes by which 4-HB is metabolized by the body. ...ichael Gibson, professor and chair of biological s... member of the research team. "It may provide new...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Gaining a better picture of lung disease 2Researchers begin to decipher metabolism of sexual assault drug 2Adam Kluger Public Relations Adds Sex Therapist and Psychiatrist Dr Dennis Lin MD to Their All Star Health and Medical Client Roster 60057 1Adam Kluger Public Relations Adds Sex Therapist and Psychiatrist Dr Dennis Lin MD to Their All Star Health and Medical Client Roster 60057 2AMERIGROUP Announces Preliminary Third Quarter Results 60054 1AMERIGROUP Announces Preliminary Third Quarter Results 60054 2AMERIGROUP Announces Preliminary Third Quarter Results 60054 3AMERIGROUP Announces Preliminary Third Quarter Results 60054 4AMERIGROUP Announces Preliminary Third Quarter Results 60054 5Insure com Inc Announces Name Change to Life Quotes Inc and Nasdaq Ticker Symbol Change to QUOT Effective October 28 2009 60051 1Insure com Inc Announces Name Change to Life Quotes Inc and Nasdaq Ticker Symbol Change to QUOT Effective October 28 2009 60051 2
...ntain codeine may be risky for some,breastfeeding ...y of Western Ontario, and the Hospital for Sick Ch...on Koren published research in the journal, Clini...at the codeine used in some pain relief drugs can ...nfants when ingested by some breastfeeding mothers...
...genetic code of a simple saltwater creature could ...nes function in humans and other species. , A stu...aks down the genetic code of Trichoplax , a simpl...in the world, even in the common household aquariu...x , genes that are also found in other animals - o...
...ide algae, Karenia brevis, costs approximately $20...t of Florida alone. Scientists at the Georgia Inst...educe the levels of the red tide,s toxicity to ani...s toxicity to other algae as well. If scientists c...y of red tide, they could reduce the vast amount o...
Other Biology News:Codeine not safe for all breastfeeding moms and their babies 2Genome of saltwater creature could aid understanding of gene grouping 2Biologists find diatom to reduce red tide's toxicity 2Biologists find diatom to reduce red tide's toxicity 3
Gey's Balanced Salt Solution (GBSS) from Sigma-Aldrich
...cations to the original formulas in efforts to pro...y an important role in tissue,culture. A salt solu...tic balance in the medium and to provide the cells...luable today as when it was first developed a cent...
Ellman's Reagent from Cayman Chemical
Synergy HT Multi-Detection Microplate Reader from BioTek Instruments
Biology Products: